1.74p
+0.58%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genflow Biosciences
Its shares trade on LSE under the ticker GENF.L. It has been listed since 17 January 2022. In the fiscal year to 31 December 2023, it reported revenue of £169,854 and a net loss of £1.6m. At that date it held total assets of £1.1m and shareholders' equity of £725,915.
Genflow Biosciences Plc operates as a biotechnology company, which engages in the research and development of gene therapies to counteract the effects of aging and diseases associated with advanced age. The firm is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The firm's product line includes GF-1002, GF-3001 and GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-Human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The firm has operations in the United Kingdom and Belgium.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Jan 2022
- Website
- genflowbio.com ↗
Leadership
Pay as last reported
- Ms. Tamara JosephNon-Executive Independent Chairman of the Board£30,000
- Dr. Eric LeireChief Executive Officer, Executive Director, since 2021£235,432
- Dr. Yassine BendiabdallahNon-Executive Independent Director, since 2023£30,713
- Dr. Guy-Charles Fanneau de la HorieNon-Executive Independent Director£30,000
- Dr. Peter King-lewisNon-Executive Independent Director£30,713
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genflow Biosciences PLC operates in the Health Care sector with a focus on Biotechnology.
- The company has developed gene therapies targeting aging using Sirtuin-6 (SIRT6) gene variants delivered via adeno-associated virus (AAV) vectors.
- Genflow Biosciences PLC has a product line including GF-1002, GF-3001, and GF-4001 for human and veterinary use.
Weaknesses
- The company's IPO occurred on January 17, 2022, indicating a relatively recent listing.
- Genflow Biosciences PLC has operations limited to the United Kingdom and Belgium.
- The company's product GF-4001 is specifically developed for veterinary use in dogs, limiting its human market application.
Opportunities
- The growing interest in gene therapies for aging and age-related diseases presents an opportunity for Genflow Biosciences PLC.
- The development of GF-1002 as an intravenous infusion therapy could expand its market reach in human healthcare.
- The company's focus on SIRT6 gene variants may align with emerging trends in anti-aging biotechnology.
Threats
- The biotechnology industry faces regulatory challenges that could impact Genflow Biosciences PLC's product development.
- Competition in the gene therapy sector may intensify as more companies enter the market.
- The company's reliance on a single gene therapy approach (SIRT6) could pose risks if alternative therapies gain prominence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.